- Home
- GIG vs TECX Comparison
GIG vs TECX Comparison
Compare GIG & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIG
- TECX
- Stock Information
- Founded
- GIG 2024
- TECX 2019
- Country
- GIG United States
- TECX United States
- Employees
- GIG N/A
- TECX N/A
- Industry
- GIG
- TECX
- Sector
- GIG
- TECX
- Exchange
- GIG NYSE
- TECX Nasdaq
- Market Cap
- GIG 346.2M
- TECX 416.0M
- IPO Year
- GIG 2024
- TECX 2018
- Fundamental
- Price
- GIG $10.38
- TECX $23.04
- Analyst Decision
- GIG
- TECX Strong Buy
- Analyst Count
- GIG 0
- TECX 5
- Target Price
- GIG N/A
- TECX $79.00
- AVG Volume (30 Days)
- GIG 86.0K
- TECX 185.5K
- Earning Date
- GIG 11-15-2021
- TECX 08-13-2025
- Dividend Yield
- GIG N/A
- TECX N/A
- EPS Growth
- GIG N/A
- TECX N/A
- EPS
- GIG 0.10
- TECX N/A
- Revenue
- GIG N/A
- TECX N/A
- Revenue This Year
- GIG N/A
- TECX N/A
- Revenue Next Year
- GIG N/A
- TECX N/A
- P/E Ratio
- GIG $99.36
- TECX N/A
- Revenue Growth
- GIG N/A
- TECX N/A
- 52 Week Low
- GIG $9.89
- TECX $13.70
- 52 Week High
- GIG $10.43
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- GIG N/A
- TECX 52.55
- Support Level
- GIG N/A
- TECX $22.09
- Resistance Level
- GIG N/A
- TECX $23.27
- Average True Range (ATR)
- GIG 0.00
- TECX 1.60
- MACD
- GIG 0.00
- TECX 0.04
- Stochastic Oscillator
- GIG 0.00
- TECX 49.87
About GIG GIGCAPITAL7 CORP.
GigCapital7 Corp is a Private-to-Public Equity (PPE) company, also known as a blank check company or special purpose acquisition company.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.